Your browser doesn't support javascript.
loading
Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner, Diane S.
Affiliation
  • Aschenbrenner DS; Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
Am J Nurs ; 121(10): 22-23, 2021 10 01.
Article in En | MEDLINE | ID: mdl-34554982
Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).This drug's approval has been highly contentious in the medical and scientific community owing to contradictory study findings and the FDA's advisory panel not recommending its approval.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Randomized Controlled Trials as Topic / Drug Approval / Alzheimer Disease / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Country/Region as subject: America do norte Language: En Journal: Am J Nurs Year: 2021 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Randomized Controlled Trials as Topic / Drug Approval / Alzheimer Disease / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Country/Region as subject: America do norte Language: En Journal: Am J Nurs Year: 2021 Document type: Article Country of publication: United States